SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
暂无分享,去创建一个
[1] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[2] S. Madsbad. Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists , 2015, Diabetes, obesity & metabolism.
[3] S. Solomon,et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.
[4] M. Pencina,et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.
[5] K. Rahimi,et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. , 2015, JAMA.
[6] Spiros Denaxas,et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people , 2015, The Lancet.
[7] M. Pfeffer,et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. , 2014, The lancet. Diabetes & endocrinology.
[8] U. Broedl,et al. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.
[9] B. Zinman,et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. , 2013, American heart journal.
[10] Craig Wilson,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.
[11] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[12] K. Mahaffey,et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. , 2013, American heart journal.
[13] Bin Wang,et al. Blood pressure‐lowering effects of GLP‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trials , 2013, Diabetes, obesity & metabolism.
[14] J. Basile. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). , 2013, Journal of diabetes and its complications.
[15] S. Poucher,et al. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus , 2013, Expert opinion on investigational drugs.
[16] L. Stevenson,et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.
[17] J. Danesh,et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.
[18] Michael E. Miller,et al. ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .
[19] N. Sattar,et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials , 2009, The Lancet.
[20] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[21] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.
[22] B. Davis,et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.